Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
TATT TAT Technologies Ltd
STOR STORE Capital Corp
NGG National Grid PLC
MDXG MiMedx Group Inc
GOGR Go Green Global Technologies Corp
APINX AMG Beutel Goodman International Equity Fund - Class N
SVBL Silver Bull Resources Inc
MYMD MyMD Pharmaceuticals Inc

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Johnson & Johnson is a diversified healthcare products company. The Company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer Health, Pharmaceutical and MedTech. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The MedTech segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.


Last Trade
0.15 (0.09%)
B/A Size

Market Hours

Closing Price
Day's Change
-6.23 (-3.70%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Bumble earnings forecast comes up light, stock tumbles

7:03 pm ET August 10, 2022 (MarketWatch)

Shares of Bumble Inc. (BMBL) were falling more than 11% in after-hours trading Wednesday after the online-dating company came up shy of expectations with its outlook for the current quarter. The company posted a net loss of $4.4 million, or 3 cents a share, compared with a loss of $7.1 million, or 6 cents a share, in the year-earlier period. Analysts tracked by FactSet were projecting a GAAP per-share loss of 1 cent. Bumble's revenue increased to $220.5 million from $186.2 million, while analysts were projecting $219.4 million. The latest quarter's revenue total included a $9.4 million negative impact from currency movements. Bumble had 3.0 million paying users in the second quarter, up from 2.9 million in the year-prior quarter. The FactSet consensus was for 3.0 million. For the third quarter, Bumble anticipates $236 million to $240 million in revenue, whereas the FactSet consensus was for $244.9 million. Bumble's revenue expectations include a projected $6 million negative impact from the war in Ukraine and a $12 million negative impact from foreign exchange. Executives also model adjusted earnings before interest, taxes, depreciation, and amortization (Ebitda) of $58 million to $60 million, while analysts were looking for $62 million. Shares of Bumble have surged 79% over the past three months, though they're off 26% over a 12-month span. The S&P 500 has risen 5.2% over three months and fallen 5.1% over 12 months.

-Emily Bary


(END) Dow Jones Newswires

August 10, 2022 19:03 ET (23:03 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.